Combined data from two phase III trials of the NK1antagonist aprepitant plus a 5HT3antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

✍ Scribed by P. J. Hesketh; S. M. Grunberg; J. Herrstedt; R. de Wit; R. J. Gralla; A. D. Carides; A. Taylor; J. K. Evans; K. J. Horgan

• Publisher: Springer-Verlag
• Year: 2006
• Tongue: English
• Weight: 124 KB
• Volume: 14
• Category: Article
• ISSN: 0941-4355
• DOI: 10.1007/s00520-005-0914-4